All In Biotech

Drug Trial Radar · NCT05648448

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Feb 22, 2023

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator

Conditions

  • Influenza
  • Influenza, Human

Interventions

  • OseltamivirDrug

    Oral oseltamivir 75mg BD for 5/7

  • FavipiravirDrug

    Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7

  • ZanamivirDrug

    Inhaled zanamivir 10mg BD for 5/7

  • BaloxavirDrug

    Oral baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0

  • MolnupiravirDrug

    Oral molnupiravir 800mg BD for 5/7

  • PeramivirDrug

    Intravenous peramivir 600mg once only

  • LaninamivirDrug

    Inhaled laninamivir 40mg once only

  • Oseltamivir and BaloxavirDrug

    Oseltamivir 75mg BD for 5/7 and Baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0

  • Oseltamivir and FavipiravirDrug

    Oseltamivir 75mg BD for 5/7 and favipiravir 1800mg BD D0 and 800mg BD for a further 4/7

  • Favipiravir and BaloxavirDrug

    favipiravir 1800mg BD D0 and 800mg BD for a further 4/7 Baloxavir: * \<80kg- single dose of 40mg on D0 * ≥80kg- single dose of 80mg on D0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of viral clearance for currently available drugs and those with potential activityTime frame: Days 0 - 5

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Universidade Federal de Minas Gerais

    Minas Gerais, Brazil · Recruiting

  • Laos-Oxford-Mahosot Wellcome Trust Research unit

    Vientiane, Laos · Recruiting

  • Sukraraj Tropical & Infectious Disease Hospital

    Kathmandu, Nepal · Recruiting

  • Faculty of Tropical Medicine, Mahidol University

    Bangkok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.